Novartis Investigative Site

Decatur, Georgia 30083

0 studies enrolling now · 15 studies all time

What they study most

Acute Gouty Arthritis, Acute Gouty Arthritis Flares, Alzheimers Disease, Atherosclerosis, Coronary Artery Disease (CAD), Coronary Atherosclerosis, Fragile X Syndrome, Heart Failure With Reduced Ejection Fraction, Moderate Clostridium Difficile Infection, Neoplasms, Breast, Relapsing Forms of Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis

Studies at this site

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients — Completed
• β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome — Completed
• Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome — Stopped early
• Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) — Stopped early
• Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients — Completed